Press Releases ClearPoint Neuro, Inc.

Equities

CLPT

US18507C1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
5.42 ^USD	-0.18%		+1.88%	-20.18%

Apr. 30	Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory	MT
Apr. 29	ClearPoint Gets FDA Clearance For Neurosurgical Equipment	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CLS partner ClearPoint Neuro receives FDA 510(k) clearance for Prism Bone Anchor Accessory enabling operating room placement of laser applicators	Apr. 30	AQ
ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory	Apr. 29	AQ
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR Stereotactic System	Apr. 25	AQ
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System	Apr. 24	AQ
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024	Apr. 23	AQ
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations	Apr. 16	GL
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)	Apr. 08	PR
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency	Mar. 20	AQ
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency	Mar. 19	AQ
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results	Mar. 12	AQ
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System	Mar. 11	AQ
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024	Mar. 04	AQ
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024	Mar. 01	AQ
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock	Mar. 01	AQ
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock	Feb. 29	AQ
ClearPoint Neuro Launches Proposed Public Offering of Common Stock	Feb. 28	AQ
ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model	Feb. 21	AQ
ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo	Jan. 24	AQ
ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe	Jan. 22	GL
ClearPoint Neuro Announces FDA Clearance for SmartFrame OR Stereotactic System	Jan. 17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ClearPoint Neuro, Inc.

Equities

CLPT

US18507C1036

Press Releases

Filters